K. Samanta

Original article Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom

S. Rule, G. Collins, K. Samanta, 2014 .

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom

S. Rule, G. Collins, K. Samanta, 2014, Journal of medical economics.

Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer

F. Percival, P. Barrett-Lee, S. Chan, 2013 .

PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings

G. Jones, L. Moore, K. Samanta, 2012 .

Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival

P. Moss, A. Lloyd, K. Samanta, 2015, Leukemia & lymphoma.

Utilities for advanced basal cell carcinoma

J. Lear, A. Lloyd, K. Samanta, 2013, Journal of medical economics.

Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.

A. Briggs, J. Ray, K. Samanta, 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries

A. Kotzeva, D. Judge, K. Samanta, 2022, Journal of medical economics.